Cytosorbents

About:

Cytosorbents develops therapeutic devices used in purifying blood to treat life-threatening diseases.

Website: http://cytosorbents.com

Twitter/X: cytosorbents

Top Investors: Avenue Capital Group, U.S. Department of Defense, Bridge Bank, U.S. Army Medical Research & Development Command

Description:

CytoSorbents Corporation is a publicly-traded, critical care focused therapeutic device company using blood purification to treat life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Each polymer bead contains millions of pores and channels that can be modified to remove substances as small as drugs, to substances as large as antibodies.

Total Funding Amount:

$105M

Estimated Revenue Range:

$10M to $50M

Headquarters Location:

Monmouth Junction, New Jersey, United States

Founded Date:

1997-01-01

Contact Email:

info(AT)cytosorbents.com

Founders:

Frank Clark

Number of Employees:

101-250

Last Funding Date:

2024-07-02

IPO Status:

Public

Industries:

© 2025 bioDAO.ai